Global Idiopathic Pulmonary Fibrosis Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Idiopathic Pulmonary Fibrosis Market was valued at $4.4 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 8.2% CAGR, to an estimated market size of $6.5 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global Idiopathic Pulmonary Fibrosis (IPF) market encompasses the pharmacological and non-pharmacological management of a chronic, progressive lung disease characterized by alveolar scarring and irreversible lung function decline. The scope includes antifibrotic agents (nintedanib and pirfenidone), emerging novel therapeutics such as PDE4B and LPA1 inhibitors, and supportive care including oxygen therapy and pulmonary rehabilitation.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Idiopathic Pulmonary Fibrosis Market in the period 2025-30:
- The global aging population is significantly expanding the patient pool as IPF incidence correlates strongly with advancing age.
- A transition is occurring from generic monotherapies toward high-cost novel mechanisms, such as PDE4B and LPA1 inhibitors.
- The FDA approval of Jascayd (nerandomilast) in late 2025 serves as a major catalyst for market growth and patient recruitment.
- Significant diagnostic advancements, including AI-enabled radiological screening and biomarker panels, are facilitating earlier disease detection.
- The market is shifting toward combination therapy paradigms, such as layering inhaled treatments over standard oral antifibrotics.
- Generic competition for pirfenidone is causing revenue erosion for branded assets while simultaneously increasing overall patient volume through improved affordability.
- Regulatory incentives like Orphan Drug Designation and accelerated approval pathways are shortening the time-to-market for innovative therapies.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Tyrosine Kinase Inhibitors (Nintedanib)
- Pirfenidone
- Novel & Pipeline Therapies